In summary, this study provides evidence for combining clinical stage RAF dimer and MEKi to achieve enhanced therapeutic activities in K‐RAS mutant tumors, warranting evaluation of coblockade of RAF dimers and MEK to maximize the clinical benefit to K‐RAS mutant tumor patients. This evidence concerns the gene RAF1 and neoplasm.